Birgitte Sogaard, Lundbeck, to Present at GTC’s Biomarker Europe Summit, Oct. 9-10, Berlin

Monrovia, CA, August 18, 2013 --(PR.com)-- Birgitte Sogaard, Divisional Director for Clinical & Quantitative Pharmacology at Lundbeck will give a presentation on “Biology Based Diagnostics within Psychiatric Diseases” at GTC’s Biomarker Europe Summit on October 9–10, 2013 in Berlin, Germany

Psychiatric diseases represent a wide spectrum of symptoms. In the current diagnostic manuals, the heterogeneity of psychiatric diseases becomes apparent. It is possible for 2 patients to fulfill the criteria for a certain disease without sharing more than one symptom. Over the years many attempts have been made to improve the understanding of the biology behind psychiatric diseases. Most approaches have been single hormone, single gene or other single cause approaches. Today it is clear that these single cause approaches will never make it, as the diseases are multifactorial. Dr. Sogaard’s presentation will highlight how transcriptomics, proteomics and metabonomics are used to establish patterns of biological characteristics that make it possible to diagnose MDD to predict treatment responses and to segment patient populations.

Dr. Sogaard has worked with Clinical Pharmacology for 25 years with focus on the establishment of biological models to be able to quantify and describe biological responses to support drug development. This includes biomarker development within a number of therapeutic areas. The focus is on building PHC into drug development.

GTC’s Biomarker Europe 2013 will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, companion diagnostics, next-generation sequencing technologies, regulatory and reimbursement issues and companion diagnostics.

For more information, please visit www.gtcbio.com/biomarkerseuro